Search hospitals > Missouri > Kansas City
Veterans Affairs Medical Center - Kansas City
Claim this profileKansas City, Missouri 64128
Global Leader in Lung Cancer
Global Leader in Cancer
Conducts research for Prostate Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
247 reported clinical trials
11 medical researchers
Summary
Veterans Affairs Medical Center - Kansas City is a medical facility located in Kansas City, Missouri. This center is recognized for care of Lung Cancer, Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Veterans Affairs Medical Center - Kansas City is involved with conducting 247 clinical trials across 353 conditions. There are 11 research doctors associated with this hospital, such as Chao H. Huang, Suman Kambhampati, Prateek Sharma, MD, and Ajay Bansal.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage I
Stage II
2Cancer
Global LeaderStage III
Stage IV
Stage II
Top PIs
Chao H. HuangUniversity of Kansas Health System Saint Francis Campus5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
19 reported clinical trials
31 drugs studied
Suman KambhampatiResearch Medical Center5 years of reported clinical research
Studies Lymphoma
Studies Leukemia
16 reported clinical trials
33 drugs studied
Prateek Sharma, MDKansas City VA Hospital1 year of reported clinical research
Studies Acid Reflux
Studies Barrett's Esophagus
10 reported clinical trials
15 drugs studied
Ajay BansalUniversity of Kansas Cancer Center1 year of reported clinical research
Studies Barrett's Esophagus
Studies Nonpolyposis Colorectal Cancer
5 reported clinical trials
7 drugs studied
Clinical Trials running at Veterans Affairs Medical Center - Kansas City
Prostate Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Multiple Sclerosis
Frailty
Kidney Disease
Diabetic Kidney Disease
Liver Disease
Ischemic Stroke
Stroke
High Dose Testosterone
for Prostate Cancer
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Recruiting3 awards Phase 2
Carboplatin vs Olaparib
for Prostate Cancer
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.
Recruiting1 award Phase 2
Systemic + Local Therapy
for Prostate Cancer
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Recruiting1 award Phase 2 & 33 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Veterans Affairs Medical Center - Kansas City?
Veterans Affairs Medical Center - Kansas City is a medical facility located in Kansas City, Missouri. This center is recognized for care of Lung Cancer, Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Veterans Affairs Medical Center - Kansas City is involved with conducting 247 clinical trials across 353 conditions. There are 11 research doctors associated with this hospital, such as Chao H. Huang, Suman Kambhampati, Prateek Sharma, MD, and Ajay Bansal.